Prolong Pharmaceuticals, LLC – Trademark Portfolio
Entity Type: 16
Prolong Pharmaceuticals, LLC holds 14 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 8 filings in this category. The portfolio also extends into Class 40 (Treatment & Processing) across 3 Nice Classification classes. Currently, 2 trademarks are registered. Notable registered marks include EPEG and SANGUINATE. The owner is based in Plainfield, NJ.
300 B Corporate Court
Plainfield, NJ 07080
Showing of trademarks Trademarks
Trademark Classifications
Prolong Pharmaceuticals, LLC's trademark portfolio spans 3 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Scientific and technological services; industrial analysis and research services
Frequently Asked Questions
How many trademarks does Prolong Pharmaceuticals, LLC have?
Prolong Pharmaceuticals, LLC has 14 U.S. trademarks filed with the USPTO. Of these, 2 registered, 6 abandoned, 6 cancelled.
What trademark classes does Prolong Pharmaceuticals, LLC file in?
Prolong Pharmaceuticals, LLC files trademarks across 3 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 40 (Treatment & Processing), Class 42 (Computer & Scientific). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are Prolong Pharmaceuticals, LLC's most well-known trademarks?
Prolong Pharmaceuticals, LLC's registered trademark portfolio includes well-known marks such as EPEG and SANGUINATE. These are among 2 currently registered trademarks in the portfolio.
What is Prolong Pharmaceuticals, LLC's trademark registration success rate?
Prolong Pharmaceuticals, LLC has a 14% trademark registration rate, with 2 out of 14 resolved applications resulting in successful registration. Currently, 0 applications are pending review.